Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) went up by 8.47% from its latest closing price compared to the recent 1-year high of $100.77. The company’s stock price has collected 8.95% of gains in the last five trading sessions. Press Release reported 15 hours ago that Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT
Is It Worth Investing in Biohaven Pharmaceutical Holding Company Ltd. (NYSE :BHVN) Right Now?
Plus, the 36-month beta value for BHVN is at 1.00. Opinions of the stock are interesting as 11 analysts out of 12 who provided ratings for Biohaven Pharmaceutical Holding Company Ltd. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $102.33, which is $30.74 above the current price. BHVN currently public float of 49.54M and currently shorts hold a 13.10% ratio of that float. Today, the average trading volume of BHVN was 665.19K shares.
BHVN’s Market Performance
BHVN stocks went up by 8.95% for the week, with a monthly drop of -9.96% and a quarterly performance of -12.66%, while its annual performance rate touched 122.41%. The volatility ratio for the week stands at 5.31% while the volatility levels for the past 30 days are set at 5.95% for Biohaven Pharmaceutical Holding Company Ltd.. The simple moving average for the period of the last 20 days is -0.52% for BHVN stocks with a simple moving average of -6.89% for the last 200 days.
Analysts’ Opinion of BHVN
Many brokerage firms have already submitted their reports for BHVN stocks, with UBS repeating the rating for BHVN by listing it as a “Buy.” The predicted price for BHVN in the upcoming period, according to UBS is $108 based on the research report published on March 11th of the current year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see BHVN reach a price target of $121. The rating they have provided for BHVN stocks is “Buy” according to the report published on December 15th, 2020.
Cowen gave a rating of “Outperform” to BHVN, setting the target price at $45 in the report published on April 17th of the previous year.
BHVN Trading at -9.91% from the 50-Day Moving Average
After a stumble in the market that brought BHVN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.20% of loss for the given period.
Volatility was left at 5.95%, however, over the last 30 days, the volatility rate increased by 5.31%, as shares sank -11.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.48% lower at present.
During the last 5 trading sessions, BHVN rose by +8.95%, which changed the moving average for the period of 200-days by -1.83% in comparison to the 20-day moving average, which settled at $71.26. In addition, Biohaven Pharmaceutical Holding Company Ltd. saw -16.75% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BHVN starting from CHILDS JOHN W, who purchase 13,157 shares at the price of $76.00 back on Mar 17. After this action, CHILDS JOHN W now owns 2,545,801 shares of Biohaven Pharmaceutical Holding Company Ltd., valued at $999,932 using the latest closing price.
CHILDS JOHN W, the Director of Biohaven Pharmaceutical Holding Company Ltd., purchase 10,000 shares at $85.14 during a trade that took place back on Mar 02, which means that CHILDS JOHN W is holding 2,532,644 shares at $851,370 based on the most recent closing price.
Stock Fundamentals for BHVN
Current profitability levels for the company are sitting at:
- -1014.33 for the present operating margin
- +72.19 for the gross margin
The net margin for Biohaven Pharmaceutical Holding Company Ltd. stands at -1205.14. The total capital return value is set at -185.55, while invested capital returns managed to touch -269.69. Equity return is now at value 594.10, with -126.40 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 86.81, with the company’s debt to enterprise value settled at 0.14. The receivables turnover for the company is 1.06 and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.18.